Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?
- PMID: 30568241
- PMCID: PMC6460577
- DOI: 10.1038/s41431-018-0309-x
Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?
Abstract
Clinical trials using somatic gene editing (e.g., CRISPR-Cas9) have started in Europe and the United States and may provide safe and effective treatment and cure, not only for cancers but also for some monogenic conditions. In a workshop at the 2018 European Human Genetics Conference, the challenges of bringing somatic gene editing therapies to the clinic were discussed. The regulatory process needs to be considered early in the clinical development pathway to produce the data necessary to support the approval by the European Medicines Agency. The roles and responsibilities for geneticists may include counselling to explain the treatment possibilities and safety interpretation.
Conflict of interest statement
The authors declare that they have no conflict of interest.
References
-
- Committee for Advanced Therapies (CAT). http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/gener.... 2018 Accessed 2 Sept 2018.
-
- Gottlieb S. Remarks by Commissioner Gottlieb to the Alliance for Regenerative Medicine’s Annual Board Meeting. https://www.fda.gov/NewsEvents/Speeches/ucm608445.htm. 2018 Accessed 2 September 2018.
-
- U.S. Food and Drug Administration. Cellular & Gene Therapy Guidances. https://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryi.... 2018 Accessed 2 September 2018.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
